<DOC>
	<DOCNO>NCT00085839</DOCNO>
	<brief_summary>The purpose noncomparative study obtain preliminary estimate efficacy erlotinib standard chemotherapy patient advance , previously untreated nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 2 . The study also evaluate safety single-agent erlotinib patient population .</brief_summary>
	<brief_title>Erlotinib vs. Standard Chemotherapy Patients With Advanced Non-small Cell Lung Cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 2</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Stage IIIB IV Nonsmall cell lung cancer ( NSCLC ) No prior chemotherapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 2 Clinically radiologically measurable disease per RECIST criterion Gastrointestinal abnormality Any concurrent anticancer therapy Prior treatment epidermal growth factor receptor ( EGFR ) inhibitor kind Other active malignancy Uncontrolled brain metastasis Severe abnormality cornea Significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>ECOG Performance Status 2</keyword>
	<keyword>erlotinib</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>OSI-774</keyword>
</DOC>